Merged operation of Cardia Bioplastics and Stellar Films Operations leads moves towards immense progress

The strategic review carried out by Cardia Bioplastics, the Australian bioplastics manufacturer leads towards the closure Brazilian plant. According to the strategic review, Cardia Bioplastics will introduce numerous strategic advantages this year. The company states that the key benefit of new strategies revolves around access of Cardia to Stellar Film’s for additional productivity. This will allow Cardia to deliver products as per the increasing demand. The biohybrid hygiene films of the company are highly in demand and these will be delivered without exclusive investments in new capital investments.

One thing to be taken under consideration here is that the merged group of Cardia and Stellar will gain profit out of the geographic presence of both the operations. There are three production plants of the company situated in China, Malaysia and Australia. All the plants have been settled well to meet growing demand of customers from Asia Pacific.

Read more about this deal here - http://www.bioplasticsmagazine.com/en/news/meldungen/20150311-Cardia-to-close-down-brazilian-operations.php

Stellar Films Operation is established and this feature of the group ensures supply of high quality products. The group also gives priority to financial resources for ensuring that the production output is optimized. The ability of Cardia to deliver the best quality product within time promotes its growth in the global market. Cardia has planned to discontinue offering fun to it’s new Brazilian plant as it keeps the merged business on priority.

7 new patents of Cardia will be proved a milestone for growth of the company

Melbourne based Cardia Bioplastics has recently added a seven protection patents to its development procedure and intellectual property. As the company has planned to patent its technology, it is on the way to become a leading manufacturer of biodegradable and compostable resins in the international packaging industry. According to the Managing Director of Cardia Bioplastics, Frank Glatz patents are important for Europe, US and Asia and in lack of patents several big firms will not be able to do business with Cardia. He further states that it is nothing but a strategic shift for the manufacturing industry to be indulged on bio-based materials rather than the oil-based plastics. These products are supposed to be environmentally sustainable and degradable.

Read more about the deal here - http://www.europeanplasticsnews.com/subscriber/newscat2.html?cat=1&channel=620&id=5384

Here the company is just looking for a technology background; the patents will let the companies that Cardia bears the technology for the materials which are desirable by the companies. In this way, patents have become trump cards without what the company will not have freedom to practice. The 7 new patents for Cardia will definitely be proved to be a milestone for the company. Began in 2002, Cardia has its production plants in Brazil, China, Sao Paulo, Nanjing while it’s headquarter is in Melbourne.

Asia will produce up to 75 percent of bioplastic by 2018 as per predictions

The capacity of bio-based plastic production has been planned to hike up to 1.6 million tons in 2013 to about 6.7 million tons by 2018. As per the conclusion of the annual market data update of European Bioplastics, the market has been predicted for over 400 percent growth in the mid-term. The compiled data with respected scientific partners, IFBB and the Nova Institute, this result has been represented during the 9th annual conference of European Bioplastics in Brussels. According to the chairman of European Bioplastics, Francois de Bie, bio-based plastics such as PET (Polyethylene Terephthalate) and PE (polyethylene) are earning more profit in terms of productions.

Read more about the deal here - http://foodnewsinternational.com/2014/12/08/world-asia-us-invest-in-creating-market-ready-bioplastics-products-finds-report/

Bio-degradable and renewable plastics manufactured are supposed to be benefitted from the innovative EU directive in case of decreasing of shopping bags. PLA has become the leading growth booster for compostable and bio-based plastics. The recently developed projects have been planned for implementation on India, China and Thailand. Flexible and sturdy packaging has special role to play in the field of bioplastics. In this entire scenario, Asia will extend its role as a leading manufacturing hub. By 2018, over 75 percent of bioplastics will be manufactured in Asia. Surprisingly, despite of being active in research and development, Europe will remain behind with about 8 percent of production efficiencies.

Cardia Bioplastics Limited to launch a new manufacturing facility in Nanjing, China

Cardia Bioplastics Limited is going to stretch its industry by moving towards an update by building a manufacturing facility in Nanjing, China. According to the company’s statement, the new factory is efficient enough to increase manufacturing capacity of about 100 million bags every year in order to meet the international demand of carry bags and hand bags by Cardia. This great increase in manufacturing capacity will be faced by Cardia Compostable and Cardia Biohybrid bags, both. The launch of new collection of Cardia bags is targeted for meeting day by ay increasing demand of hygienic and custom products. Read full story about the same here at –

http://www.cardiabioplastics.com/news/13/80/2014-06-24/cardia-bioplastics-successfully-completes-relocation-to-new-purpose-built-factory-and-installation-of-three-new-production-lines-/?page=1

According to the statement of Jackie Chen, general manager of Cardia Bioplastics China, the company feels excited to launch the new manufacturing facility in Nanjing. As the management is committed for delivering increasing orders, quick processing in the business for expected growth is necessary. Similarly, Richard Tegoni, the chairman of the company states that the newly opening manufacturing wing is really a big milestone for the company as it promotes growth and development of the company by offering it the chance of elaborating its capacity by manufacturing of high quality finished products. That’s why; the company always focuses to plan a strategy of doubling up its production.